Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

Rexlemestrocel-L

Source date not recordedAnalyse record ↗

Allogeneic mesenchymal precursor cell therapy in confirmatory Phase 3 follow-up for inflammatory degenerative disc disease.

Modality
allogeneic mesenchymal precursor cell therapy delivered with hyaluronic acid
Availability (US)
Confirmatory Phase 3 chronic-low-back-pain study Active, not recruiting
Biomarkers
daily average low-back-pain score; treatment-emergent adverse events; physical function and quality-of-life measures
Hallmark targeted
stem-cell signaling, extracellular-matrix repair, chronic inflammation, disc degeneration
Kind
investigational cell therapy
Clinical trials
NCT06325566 — Phase 3, Active, not recruiting on June 17, 2026 registry update